The ability to deliver curative chemotherapy to children with malignant disease who have hepatic or renal failure poses major problems. If an anti-cancer agent, or its active metabolites, is excreted by the kidney, administration in conventional dosage can cause significant toxicity, so dose reduction is necessary. In contrast, drugs such as vincristine, doxorubicin, cyclophosphamide and actinomycin D which are eliminated by other routes can be given in standard doses in renal failure. Although drugs which are eliminated by the kidney without extensive prior metabolism can be administered to patients with renal failure by using pharmacokinetic or therapeutic drug monitoring, the effects of concomitant peritoneal and haemodialysis must be considered. This report describes the treatment of two patients with Wilms' tumours, who had chronic renal failure requiring dialysis, with carboplatin and etoposide, two drugs which undergo significant renal clearance. Case reports Patient 1 was a 4.3-year-old girl who presented with haematuria and a rapidly enlarging abdominal mass. A stage III Wilms' tumour of the left kidney with favourable histology was removed at laparotomy, but it involved the abdominal aorta, which ruptured during the operation. The aorta was repaired but the right kidney had suffered severe ischaemic damage and she developed renal failure. She was established on peritoneal dialysis and treated with vincristine, actinomycin D and doxurubicin for 1 year, but did not receive radiotherapy. Two months after discontinuing treatment her tumour recurred with the development of loin pain, blood staining of her dialysis fluid and a mass involving para-aortic lymph nodes in her left renal bed.
Patient 2 was a 17-year-old male who was found to have a left-sided abdominal mass and iron deficiency anaemia at a routine medical examination. At the age of 2 he had been treated for a right-sided Wilms' tumour ( (de Camargo et al., 1994; Ettinger et al., 1994; Pein et al., 1993; Pinkerton et al., 1985) , but ifosfamide may cause severe encephalopathy when given to patients with renal failure (Mermimsky et al., 1992) . The combination of carboplatin and etoposide represented the most active combination of drugs not already used in these patients (Pein et al., 1994) .
Pharmacokinetic monitoring with adaptive control of dosing by feedback, rather than conventional dosing according to body weight or surface area, was used to achieve a target area under the drug plasma concentration against time curve (AUC) in both patients, because the pharmacokinetics of both carboplatin and etoposide is markedly affected by renal function.
Methods

Calculation of target AUC values
For each drug the AUC associated with the administration of a standard dose to patients with normal renal function was calculated. For carboplatin a dose of 450 mg m-2 was chosen, for which the median AUC would be approximately 6 mg ml-' min (Newell et al., 1993) . AUC-based dosing of children with etoposide had not been reported at the time these patients were treated, and target AUCs were chosen based upon a large number of previous studies in this centre (Lowis et al., 1993 
Haematological toxicity
Toxicity was coded according to common toxicity criteria.
The total white cell count, absolute neutrophil count (ANC) and platelet count were determined every 2 -3 days at the time patients attended for dialysis. Toxicity from anaemia in these patients has not been considered separately because of the additional influence of chronic renal failure.
Results
Pharmacokinetic data for the first cycle of carboplatin and etoposide in patient 1 and for three out of six cycles in patient 2 are given in Table I . The dose on day 1 was given based on the assumption of no renal function and subsequent doses were modified on the basis of the results of the pharmacokinetic analyses. On course 1 in both patients the total target AUCs during the course were achieved with a high degree of accuracy: measured AUCs of 6 and 21 mg ml-' min for carboplatin and etoposide against target AUCs of 6 and 18 mg ml-' min for patient 1; and measured AUCs of 6 and 20 mg ml-1 min against target AUCs of 6 and 21 mg ml-' min for patient 2 respectively. The dose of carboplatin was reduced by 25% after course 1 for patient 2 because of haematological toxicity. A smaller etoposide dose was given on course 4 because of reduced clearance. As can be seen, carboplatin was cleared by haemodialysis but etoposide was not, and neither drug was cleared by peritoneal dialysis.
Pharmacokinetic profiles for the first cycles of carboplatin and etoposide in both patients are shown in Figures 1-4 . Patient 1 had some residual renal function with a 51Cr EDTA clearance of 2 ml min-' (5.2 ml min-' 1.73 m-2). Consistent with the residual renal function in this patient, the urinary elimination of carboplatin and etoposide accounted for 30% and 6% of the administered doses, respectively. The plasma clearance of carboplatin was 5 ml min-1 (carboplatin and 5"Cr EDTA were administered simultaneously).
Patient 2 required early haemodialysis 10 h after the initial dose of carboplatin had been given because of hyperkalaemia. Haemodialysis, applied 10 h after the dose of carboplatin, increased the total clearance of free drug such that an AUC of only 2.7 mg ml-1 min was achieved. If no haemodialysis was applied the projected AUC following this dose would have been 4 mg ml-' min. When the dose was repeated on day 3, with dialysis applied at the same time after the carboplatin dose and for the same duration, the AUC was 3.3 mg ml-1 min. Thus, by monitoring the pharmacokinetics of free carboplatin and applying haemodialysis in a consistent manner we were able to achieve the target AUC of 6 mg ml-' min. Carboplatin, etoposide and dialysis MW English et al dialysis. It is possible to achieve target AUCs for both drugs using pharmacokinetic monitoring so that effective drug levels are reached with acceptable toxicity.
Although previous reports have monitored the pharmacokinetics of carboplatin in renal failure (Koren et al., 1993; Motzer et al., 1990) there has been only one report of targeted dosing of carboplatin (to an AUC of 6 mg ml-1 min) in a patient with ovarian carcinoma and renal failure (Chatelut et al., 1994) . In the patients reported in this present study carboplatin was not cleared from plasma by peritoneal dialysis but was cleared by haemodialysis, confirming previous studies Koren et al., 1993; Motzer et al., 1990) .
Patients who have residual renal function will be underdosed by the dosing formula used here if it is assumed that their GFR is zero. The complete formula takes account of both renal and non-renal clearance (Newell et al., 1993) al., 1994; Hall et al., 1994; Koren et al., 1993; Motzer et al., 1990) . It was intended to wait 24 h before patient 2 was dialysed and his dose of carboplatin was calculated to give an AUC of 6 mg ml-' min assuming no effect from dialysis. Despite good dietary control hyperkalaemia developed soon after the start of chemotherapy and dialysis was necessary 10 h after the completion of the first dose of carboplatin, resulting in an AUC of only 2.7 mg ml-1 min. However, pharmacokinetic monitoring made it possible to give an additional dose of carboplatin to achieve the intended AUC.
Cisplatin has also been used to treat patients with renal failure on haemodialysis (Fox et al., 1991; Ribrag et al., 1993; Tanabe et al., 1994 (Tanabe et al., 1994) . The active agent for both cisplatin and carboplatin is the free platinum drug that is hydrolysed before it binds to DNA or protein. Cisplatin is hydrolysed 10-20 times faster than carboplatin and the main route of clearance of free cisplatin is by binding to macromolecules. In spite of this, when renal function deteriorates the plasma clearance of free platinum drops (Reece et al., 1986) , and in one anephric patient the plasma clearance of free platinum was five times lower than in individuals with normal renal function (Tanabe et al., 1994) . Thus, adaptive control of cisplatin can be used in patients with renal failure. Cisplatin has been shown to be active against relapsed Wilms' tumour in a few cases (Marina et al., 1994) , however carboplatin was chosen in the present study because there are more phase II studies demonstrating its activity against Wilms' tumour (de Camargo et al., 1994; Ettinger et al., 1994) and there was more experience with targeted dosing of carboplatin in children (Marina et al., 1993; Newell et al., 1993) and adults .
Etoposide is normally eliminated by renal (60%) and hepatic (40%) mechanisms (Joel et al., 1994) . Renal impairment is predictive of toxicity in patients receiving etoposide (Clark et al., 1988) , and a dose reduction of 50% has been suggested in all patients with poor kidney function (D'Incalci et al., 1986 Koren et al. (1993) which underlines the importance of identifying a target AUC and then monitoring the achieved AUC.
In conclusion, treatment with carboplatin and etoposide is possible in patients with renal failure who require dialysis, however in this situation pharmacokinetic monitoring is essential. Timing of the peritoneal dialysis or haemodialysis relative to the administration of etoposide is not important. However the timing of haemodialysis, but not peritoneal dialysis, has a critical effect on the AUC of carboplatin. Further studies are required to define the optimum AUCs of carboplatin and etoposide required to achieve a response with acceptable toxicity in paediatric tumours. Until such studies are performed, targeted dosing of carboplatin to an AUC of 6 mg ml-' min and etoposide to a total AUC of 21 mg ml-I min is recommended as a schedule that produces significant, but manageable toxicity.
